Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC

Exclusion Criteria

• •WHO performance status ≥ 2
• •FEV-1 and DLCO \< 35 % of the age- and gender adjusted normal value
• •Patients with grade 3 dyspnea or worse at baseline (according to CTCAE version 4.03)
• •Prior radiotherapy to the thorax.
• •Mean lung dose \> 20.0 Gy and/or exceeding other organs-at-risk constraints (page 21).
• •Participation in another clinical study with an investigational product during the last 4 weeks.
• •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study
• •Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of chemotherapy.
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent
• •Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
• •Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control
• •Any condition that, in the opinion of the investigator, would interfere with evaluation of the chemoradiotherapy or interpretation of patient safety or study results.